LDLR promotes autophagy‐mediated cisplatin resistance in ovarian cancer associated with the PI3K / AKT / mTOR signaling pathway
The Kaohsiung Journal of Medical Sciences · 2023
DOI: 10.1002/kjm2.12696 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2023. Verfasst von Lei Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, People's Republi…. Hauptthemen laut MEDLINE: Cisplatin, Ovarian Neoplasms, Receptors, LDL. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Autophagy is one of the underlying causes of resistance to many antitumor drugs, including cisplatin (DDP). The low‐density lipoprotein receptor (LDLR) is a regulator of ovarian cancer (OC) progression. However, whether LDLR regulates DDP resistance in OC via autophagy‐related pathways remains unclear. LDLR expression was measured by quantitative real‐time PCR, western blot (WB) and IHC staining. A Cell Counting Kit 8 assay was employed to evaluate DDP resistance and cell viability, and flow cytometry was used to assess apoptosis. WB analysis was employed to evaluate the expression of autophagy‐related proteins and PI3K/AKT/mTOR signaling pathway proteins. The autophagolysosomes and the fluorescence intensity of LC3 were observed by transmission electron microscopy and immunofluorescence staining, respectively. A xenograft tumor model was established to explore the role of LDLR in vivo. LDLR was highly expressed in OC cells, which was correlated with disease progression. In DDP‐resistant OC cells, high LDLR expression was related to DDP resistance and autophagy. Downregulation of LDLR repressed autophagy and growth in DDP‐resistant OC cell lines by activating the PI3K/AKT/mTOR pathway, and these effects were eliminated by an mTOR inhibitor. In addition, LDLR knockdown also reduced OC tumor growth by suppressing autophagy associated with the PI3K/AKT/mTOR pathway. LDLR promoted autophagy‐mediated DDP resistance in OC associated with the PI3K/AKT/mTOR pathway, indicating that LDLR might be a new target to prevent DDP resistance in OC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
- Department of Pathology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, People's Republic of China.
ORCID-Profile: Jian-Hua Zheng
Zitieren
APA
Liu, L., Sun, Y. H., An, R., Cheng, R. J., Li, N., & Zheng, J. H. (2023). LDLR promotes autophagy‐mediated cisplatin resistance in ovarian cancer associated with the PI3K / AKT / mTOR signaling pathway. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12696
Vancouver
Liu L, Sun YH, An R, Cheng RJ, Li N, Zheng JH. LDLR promotes autophagy‐mediated cisplatin resistance in ovarian cancer associated with the PI3K / AKT / mTOR signaling pathway. The Kaohsiung Journal of Medical Sciences. 2023. doi:10.1002/kjm2.12696
BibTeX
@article{Liu2023,
author = {Liu, Lei and Sun, Yu-Hui and An, Ran and Cheng, Rong-Jie and Li, Nan and Zheng, Jian-Hua},
title = {LDLR promotes autophagy‐mediated cisplatin resistance in ovarian cancer associated with the PI3K / AKT / mTOR signaling pathway},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2023},
doi = {10.1002/kjm2.12696}
}
EUVIMED